Edgewise Therapeutics announced the sale of Sevasemten for up to $2.65 billion, strengthening its balance sheet and centering the company on its cardiovascular pipeline.
Edgewise Therapeutics is dedicated to developing new medicines for serious cardiovascular diseases with unmet medical needs, focusing on muscle pathology and innovative therapeutic approaches
Edgewise Therapeutics is dedicated to developing new medicines for serious cardiovascular diseases with unmet medical needs, focusing on muscle pathology and innovative therapeutic approaches.